吉非替尼对晚期非小细胞肺癌治疗后出现耐药后行不同治疗方案的疗效分析及预后评估被引量：1

Curative effect of Gefitinib and prognosis evaluation for different treatment strategies in advanced non small cell lung cancer therapy resistance

下载PDF

导出

摘要目的探讨非小细胞肺癌接受吉非替尼治疗出现耐药性后行不同的治疗方案,评估其疗效及对预后的影响。方法通过回顾性分析在随访时间内,120例经吉非替尼治疗后的患者出现对该药的耐药,随机分为不同的治疗方案,即化疗组(NP方案+吉非替尼)和单纯口服吉非替尼组,通过术后实验室检查、毒副反应进行规律随访及评估。结果出现耐药后经生存分析化疗组生存时间明显长于单纯服用吉非替尼组,化疗组和单纯口服吉非替尼方案的总生存期为29.06和15.23个月,两组相比差异有统计学意义(P<0.05);对影响患者生存率的独立危险因素分析表明,多发转移、期间是否接受化疗是影响患者生存率的独立危险因素。结论化疗组比单纯口服吉非替尼组治疗晚期非小细胞肺癌的生存时间长,有较好的安全性及有效性,同时,多因素分析多发转移、期间是否接受化疗是影响术后生存率主要的危险因素。 Objective： To investigate the non small cell lung cancer treated with gefitinib treatment and evaluate its effect on prognosis. Methods： By retrospective analysis in the follow-up time,120 cases after gefitinib therapy patients who appeared resistant to the drug,were randomly divided into the different treatment plans,namely the chemotherapy group（ NP program ＋ gefitinib） and simple oral gefitinib group,regular follow-up and evaluation were made through after laboratory tests and adverse reaction. Results： The drug resistance after survival analysis of survival time was significantly longer than that of the pure chemotherapy group,and chemotherapy group and simple oral gefitinib overall survival plans were 29. 06 and 15. 23 months and there was significant difference between the two groups（ P 〈 0. 05）; The analysis showed that multiple metastases and chemotherapy were independent risk factors for the survival rate of the patients. Conclusion： The survival time of the chemotherapy group is long,which is safe and has efficacy,and multiple metastases and chemotherapy are the major risk factors influencing survival rate after operation.

作者陈霞

机构地区泰安荣军医院

出处《泰山医学院学报》 CAS 2016年第1期17-20,共4页 Journal of Taishan Medical College

关键词非小细胞肺癌吉非替尼疗效预后 non small cell lung cancer gefitinib curative effect prognosis

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献13

1Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010 [J]. CA Cancer J Clin, 2010, 60(5): 277-300.
2Tiseo M, Rossi G, Capelletti M, et al. Predictors of gefitinib out- comes in advanced non-small cell lung cancer (NSCLC) : study of a comprehensive panel of molecular markers [ J ]. Lung Cancer, 2010, 67(3) : 355 -360.
3王彬,张昕,林琳,郝学志,张湘茹,李峻岭,石远凯.吉非替尼治疗晚期非小细胞肺癌耐药后的进展模式分析[J].中国肺癌杂志,2013,16(10):510-513. 被引量：3
4Fossella DV, DeVore R, Kerr R.N, et al. Randomized phaseatrialofdocetaxelversus vinorelbine or ifosfamide in patldnts with advanced non-small cell lung cancer previous treated with platinum-containing chemotherapy regimens [ J ]. J Clin Oncol, 2000, 18(12) : 2354 -2362.
5林宝钗,洪卫,张沂平.表皮生长因子受体-酪氨酸激酶抑制剂治疗晚期NSCLC的耐药机制及治疗对策[J].中国药学杂志,2013,48(7):501-504. 被引量：6
6National Comprehensive Career Network. Non-Small Cell Lung Cancer Panel Members [J]. NCCN Clinical Practice Guidelines in Oncology Non - Small Cell Lung 2010[ 2012 -06 -21 ]. Cancer Version 1. 2010[ M/OL].
7FukuokaM, Yano S, Giaccone G, et al. Multi- institutional ran- domized phase trial of gefitinib for previously treated patientswith advanced non-small cell lung cancer( the IDEAL Trial) [ J]. J Clin Oncol, 2003, 21 (12):2237-2246.
8Kris MG, Natale RB, Herbst RS, eta/. Effeacy of getatinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patientswith non-small eelllung cancer: a randomized trial [ J]. JAMA,2003, 290(16):2149-2158.
9KIM ES, HIRSH V, MOK T, et al. Gefitinib vemus doeetaxel in previously treated non-small cell lung eaneer(INTEREST) : aran- domised phase Ⅲ trial[ J ]. Lancet,2008,372 ( 9652 ) : 1809 - 1818.
10SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T, et al. Erlotinib in previously treated non-small cell lung cancer[ J ]. N Engl J Med,2005,353(2) : 123 -132.

二级参考文献63

1OWONIKOKO TK, RAGIN CC, BELANI CP, et al. Lung canc-er in elderly patients : an analysis of the surveillance, epidemiolo- gy, and end results database[ J]. J Clin Oncol, 2007, 25 (35) : 5570 - 5577.
2GRIDELLI C, PERRONE F, MONFARDINI S. Lung cancer in the elderly[J]. Ettr JCancer, 1997, 33(14): 2313 -2314.
3ULRICH W, FRIEDEMANN H, CARSTEN B, et al. Tolerance to chemotherapy in elderly patients with cancer[ Jl. Cancer Con- trol, 2007, 14( 1 ) : 44 - 56.
4TISEO M, ROSSI G, CAPELLETTI M,et al. Predictors of ge- fitinib outcomes in advanced non-small cell lung cancer (NSCLC) : study of a comprehensive panel of molecular markers [J]. Lung Cancer, 2010, 67(3) :355 -360.
5CRIN0 L, CAPPUZZO F, ZATLOUKAL P. Gefitinib versus vi- norelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE) : a randomized, phase II study[J]. JClin Oncol, 2008, 26(26): 4253 -4260.
6JACKMAN DM, YEAP B, LUCCA J, et al. Phase II trial of er- lotinib in elderly patients ( age > 70 ) with previously untreated advanced non-small cell lung cancer (NSCLC) : An analysis of quality of life and symptom response [ J 1. J Clin Oncol, 2006, 24(18s) : abstr7168.
7MERIMSKY O, CHENG C, RECK M, et al. Erlotinib as lst- line therapy for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) [ J]. J Clln Oncol, 2008, 26 (Suppl abstr) : 19016.
8KIM ES, HIRSH V, MOK T, et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer (INTEREST) : a randomised phase III trial [ J ]. Lancet, 2008, 372 (9652) : 1809 - 1818.
9SHEPHERD FA, RODRIGUES PEREIRA J, CIULEANU T, et al. Erlotinib in previously treated non-small cell lung cancer[ Jl N Engl J Med, 2005, 353(2) : 123 -132.
10THATCHER N, CHANG A, PARIKH P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomised, placebo-controlled, multicentre study ( Iressa Survival Evaluation in Lung Cancer) [J]. Lancet, 2005, 366 (9496) : 1527 - 1537.